['migraine headache']
['galcanezumab', 'placebo']

        Inclusion Criteria:

          -  Participants with a history of migraine of at least 1 year prior to enrollment.

          -  Migraine onset prior to age 50.

        Exclusion Criteria:

          -  Current enrollment in, or discontinuation within the last 30 days from, a clinical
             trial involving any investigational drug or device.

          -  Current use or any prior exposure to any CGRP antibody, any antibody to the CGRP
             receptor, or antibody to nerve growth factor (NGF).

          -  History of migraine subtypes including hemiplegic migraine, ophthalmoplegic migraine,
             and basilar-type migraine.

          -  Have a history or presence of other medical illness that indicates a medical problem
             that would preclude study participation.

          -  Failure to respond to more than two adequately dosed effective migraine prevention
             treatments.

          -  Evidence of significant active psychiatric disease, in the opinion of the
             investigator.

          -  Women who are pregnant or nursing.
      